You are here: Industry Insights > Brilinta

News List

AZ’s Brilinta reduced rate of stroke and death in high-risk subgroup pharmatimes
November 19, 2020
AstraZeneca’s P2Y12 receptor antagonist Brilinta reduced the rate of stroke and death in a prespecified, high-risk subgroup, according to new analysis of the phase III THALES trial.
Brilinta Approved to Reduce Stroke Risk americanpharmaceuticalreview
November 17, 2020
AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk ...
US green lights AZ’s Brilinta to reduce risk of stroke pharmatimes
November 10, 2020
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Brilinta (ticagrelor) to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischaemic attack (TIA).
Brilinta significantly reduced rate of composite of stroke and death in THALES trial pharmaceutical-business-review
July 21, 2020
Detailed results from the positive Phase III THALES trial showed AstraZeneca’s Brilinta (ticagrelor) 90mg used twice daily and taken with daily aspirin for 30 days, reduced the rate of the primary composite endpoint of stroke and death by 17% (HR 0.83 ...
Brilinta Granted FDA Priority Review americanpharmaceuticalreview
July 21, 2020
AstraZeneca announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Brilinta (ticagrelor) for the reduction of subsequent stroke in patients ...
AZ unveils detailed data from THALES trial pharmatimes
July 16, 2020
AstraZeneca has now shared detailed results from the Phase III THALES, showing that a combination of twice daily Brilinta (ticagrelor) and daily aspirin reduced the rate of stroke and death (the composite primary endpoint) by 17% after 30 days ...
US priority review for AZ' Brilinta/aspirin combination pharmatimes
July 14, 2020
The US Food and Drug Administration has agreed to a speedy review of AstraZeneca's Brilinta (ticagrelor) for the reduction of subsequent stroke in patients who have experienced an acute ischaemic stroke or transient ischaemic attack (TIA).
AstraZeneca’s heart disease drug Brilinta gets FDA approval pharmaceutical-technology
June 02, 2020
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for Brilinta (ticagrelor) to decrease the risk of a first heart attack or stroke in high-risk patients suffering from coronary artery disease (CAD).
Brilinta found to reduce bleeding vs dual therapy pharmatimes
April 01, 2020
AstraZeneca has announced that the Phase IV independent TWILIGHT trial, Brilinta (ticagrelor) monotherapy reduced bleeding complications with no increased risk of ischaemic events in patients with diabetes undergoing percutaneous coronary intervention.
AstraZeneca announces its Brilinta reduced MACE in CAD and type 2 diabetes patients pharmaceutical-technology
February 26, 2019
Global pharmaceutical company AstraZeneca has announced its drug Brilinta (ticagrelor) in combination with aspirin has met its primary endpoint, a statistically significant reduction in major adverse cardiovascular events, in the Phase III THEMIS trial...

Previous page 1 2 Next page